New technology from Response Scientific offers solution to opioid drug epidemic PRINCETON, NJ, June 28, 2017 (GLOBE NEWSWIRE) -- Response Scientific, Inc.® (RSI) announced today it has developed a solution to the massive illicit black-market opioid drug epidemic plaguing...

ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye SAN FRANCISCO, June 19, 2017 (GLOBE NEWSWIRE) -- Today ProLynx LLC announced a collaboration with Daiichi Sankyo Company, Limited to evaluate its drug delivery linker technology in the eye.    In...

ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at the 77th American Diabetes Association meeting in San Diego, ProLynx LLC announced a novel drug delivery system to...

ProLynx issued US patent for cleavable linker technology on hydrogels SAN FRANCISCO, May 30, 2017 (GLOBE NEWSWIRE) -- ProLynx LLC today announced that the United States Patent and Trademark Office has issued US Patent 9,649,385 entitled “Hydrogels with Biodegradable...

ProLynx Awarded NSF Supplement to Develop Its Hydrogel Drug Delivery System to Treat Inner Ear Disorders SAN FRANCISCO, June 29, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension, announced the receipt of a...